Adriana H Tremoulet
UCSD · University of California, San Diego
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adriana H Tremoulet as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:14 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02179853 · Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki DiseaseUniversity of California, San Diego · completed · Kawasaki Disease · principal investigator
- Ph3NCT00760435 · Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki DiseaseUniversity of California, San Diego · completed · Kawasaki Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CTSA K12 Program at University of California San Diego Altman Clinical and Translational Research InstituteK12TR005441 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $1,612,278 awarded in 2026Same name and institution; not confirmed by an ID
- Project 1: ClinicalP50HD106463 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2021 to 2026 · $185,390 awarded in 2026Same name and institution; not confirmed by an ID
- UC San Diego Raising Advancement and Parity for Infectious Disease Researchers (RAPID) Faculty Development ProgramR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $378,762 awarded in 2026Same name and institution; not confirmed by an ID
- Academic Training in Therapeutic Advancement for Child Health (ATTACH)T32HD087978 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2016 to 2025 · $189,669 awarded in 2025Same name and institution; not confirmed by an ID
- 14th Annual International Kawasaki Disease Symposium 2024R13HL174111 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2024 · $7,500 awarded in 2024Same name and institution; not confirmed by an ID
- Diagnosing and predicting risk in children with SARS-CoV-2- related illnessR33HD105590 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2023 · $410,937 awarded in 2023Same name and institution; not confirmed by an ID
- Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki DiseaseR01HL140898 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2018 to 2022 · $729,091 awarded in 2022Same name and institution; not confirmed by an ID
- Pediatric and Developmental Pharmacology for Inflammatory and Infectious DiseasesP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2019 to 2020 · $711,940 awarded in 2020Same name and institution; not confirmed by an ID
- Pediatric and Developmental Pharmacology for Inflammatory and Infectious DiseasesU54HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2016 to 2018 · $734,233 awarded in 2018Same name and institution; not confirmed by an ID
- Phase I and IIa trial of atorvastatin in children with acute Kawasaki diseaseR01HD081296 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2014 to 2017 · $300,795 awarded in 2017Same name and institution; not confirmed by an ID
- Pharmacologic Determinants for Optimized Therapy in HIV-Infected ChildrenK23HD056939 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2007 to 2011 · $121,770 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:14 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 233 citationsRCR 9.1
- Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.J Pediatr · 2011132 citationsRCR 5.0
- miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.Circ Res · 2017107 citationsRCR 4.0
- Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.Lancet Child Adolesc Health · 202185 citationsRCR 5.5
- Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).Contemp Clin Trials · 201658 citationsRCR 2.1
- Specificity of regulatory T cells that modulate vascular inflammation.Autoimmunity · 201455 citationsRCR 1.7
- Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.J Pediatr · 202241 citationsRCR 3.8
- Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.Clin Exp Immunol · 201339 citationsRCR 1.2
- Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.J Pediatr · 201929 citationsRCR 1.4
- Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children.BMC Pediatr · 201624 citationsRCR 1.0